HEALTHQUARTZ
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial. The mRNA-based vaccine combined with Keytruda was shown to reduce melanoma recurrence in over 1,100 patients. These patients were those whose cancer had been surgically removed.
Mentioned
Related Signal
Adjacent reporting
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
- Personalized mRNA vaccine shows promise in reducing melanoma return: Research
- Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%
- Moderna share price doubles on melanoma vaccine trial success
- Cancer vaccine slashes risk of deadly skin cancer returning by nearly half in major trial
- A cancer vaccine made just for you. mRNA is back and it's fighting melanoma